DRKS00005594已完成2 期
Aprepitant in histamine-refractory chronic pruritus: a multicenter, randomized, double-blind, placebo-controlled, cross-over, phase II trial (APREPRU) - APREPR
niversitätsklinikum Münster0 个研究点目标入组 58 人开始时间: 2014年1月16日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 58
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 70 Years（—）
- 性别
- All
入选标准
- •1. Age: 18 - 70 years, both gender
- •2. Patients with generalized chronic pruritus (being actively present for at least 6 weeks prior to screening) AND showing prurigo nodularis of dermatological, systemic or mixed origin
- •3. Pruritus was refractory* to a four-week systemic antihistamine therapy (by history, any antihistamine; *no reduction of pruritus by more than two points on VAS)
- •4. VAS = 7 (in average during one of the past two days) at Baseline
- •5. Signed informed consent
- •6. Male patients agree to use a reliable method of birth control during the study.
- •7. If the subject is a female of childbearing potential who:
- •- has been strictly abstinent 1 month prior to baseline (V2) and agrees to continue for the duration of the clinical trial and for 2 months after end of study
- •- and/or agrees to use a highly effective and approved contraceptive method(s) for the duration of the study and for 2 months after end of the study.
- •A highly effective method of contraception is defined as:
- •o combined oral contraceptives (estrogens and progesterone) or implanted or in-jectable contraceptives with a stable dose for at least 1 month prior to Baseline visit AND use of preservative or
- •o bilateral tubal ligation
- •o or hormonal intra-uterine device (IUD) inserted at least 1 month prior to Base-line visit AND use of preservative
- •o or vasectomized partner for at least 3 months prior to baseline
- •Female of non-childbearing potential, defined as post menopausal (absence of menstrual bleeding for one year without any other medical reasons), hysterectomy or bilateral oophorectomy at Screening and Baseline visit
排除标准
- •1. Patients with
- •a. chronic pruritus of paraneoplastic, neurogenic, and psychogenic origin
- •b. pruritus of dermatologic origin with severe skin inflammation necessitating systemic anti-inflammatory therapy, for example urticaria, bullous pemphigoid, acute generalized flaring up in atopic dermatitis.
- •c. localized pruritus (only a single area involved)
- •2. Current clinically significant cardiovascular, respiratory, neurologic, hepatic, hematopoietic, renal, gastrointestinal or metabolic dysfunction and/or disease unless currently controlled and stable
- •3. Subjects with an underlying known disease, a surgical or medical condition, which in the judgement of the Investigator, would put the subjects at risk (e.g., uncontrolled chronic or serious diseases which would normally prevent participation in any clinical study or might confound the study assessments (e.g. other dermatological diseases), or might interfere with the subject’s study participation (e.g. planned hospitalization during the study) at Screening and Baseline visits
- •4. Subjects with clinically significant abnormal laboratory values according to the Investigator at Screening visit
- •5. Current psychosomatic and psychiatric diseases
- •6. Current malignant disease and chemotherapy (e.g., hodgkins lymphoma during therapy)
- •7. Chemotherapy with etoposide, vinorelbine
- •8. Current and past use of topical (washout period 2 weeks) or systemic steroids (washout period 4 weeks) before baseline
- •9. Current and past use before baseline of topical and systemic antihistamines such as cetirizine or loratadine (washout period 2 weeks) [remark: During the study the intake of cetirizine as rescue medication is allowed.]
- •10. Current and past use before baseline of the following systemic drugs (washout period 4 weeks): ultraviolet A or B light therapy, cyclosporin A and other immunosuppressants, antiepileptics (e.g., midazolam) and anti-cholinergics, antidepressants, pain modulators (gabapentin/pregabalin), opioid receptor agonists or antagonists, anti-anxiety drugs, tranquilizers, hypnotics, antipsychotic drugs (e.g., pimozide)
- •11. Current and past use before baseline and planned intake during the study of the following drugs (washout period 4 weeks):
- •- drugs strongly inducing CYP3A4 activity (e.g. rifampicin, phenytoin, carbamazepine, phenobarbital, St. John’s Wort (Hypericum perforatum, Johanniskraut”),
- •- ketoconazole, itraconazole, voriconazol, posaconazol, clarithromycin, telithromycin, nefazodon, protease inhibitors, irinotecan
- •- pimozid, terfenadine, astemizole, cisapride
- •- tacrolimus, sirolimus, everolimus, alfentanil, dihydroergotamin, ergotamin, fentanyl, chinidin
- •- warfarin, phenprcoumon, midazolam, alprazolam, triazolam, acenocoumarol, tolbutamide
- •12. Pregnancy, breast feeding
- •13. Subjects currently enrolled in another investigational drug or device study or participated in such a study in the month prior to Baseline visit.
- •14. Known hypersensitivity to aprepitant or to any of the excipients, especially sucrose (e.g. patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency).
研究者
相似试验
进行中（未招募）
不适用
Aprepitant in chronic itching in the case of unsuccessful pretreatment with antihistamines: a multicenter, randomized, double-blind, placebo-controlled, cross-over, phase II trialEUCTR2013-001601-85-DEniversity Hospital Münster
尚未招募
不适用
The effect of anti-histamine drug to chronic urticariaurticariaJPRN-UMIN000004247Kyoto University Graduate School of Medicine200
已完成
不适用
Conditioning AntihistamineItch, conditioningJeuk, conditionerenNL-OMON27241eiden University92
已完成
不适用
Conditioning of antihistaminergic effectsHet onderzoek wordt bij gezonde proefpersonen uitgevoerd. Uitkomsten uit deze lijn van onderzoek bieden nieuwe handvatten voor verklaringsmodellen en therapeutische interventies voor allergene aandoeningen waarbij een verandering in de histaminerespons optreedt.NL-OMON42660niversiteit Leiden92
撤回
4 期
Systemic antihistamines in the treatment of attention-deficit/hyperactivity disorder (ADHD): a pilot study.allergyADHDattention deficit and hyperactivity disorder1000170810009841NL-OMON42065Medisch Centrum Leeuwarden60